期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 28, 期 5, 页码 197-199出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2007.03.003
关键词
-
Progress in understanding the genetic changes that drive tumorigenesis has enabled the development of molecularly targeted anticancer therapy. The first small molecule targeted to a specific protein was imatinib mesylate (Gleevec, ST1571), which is used to treat chronic myeloid leukemia (CML). A recent article presents a computational model with which to study the treatment response in CML patients and investigates the effect that imatinib exerts on leukemic stem cells. Here, I discuss insights derived from this study and their implications for imatinib therapy against CML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据